UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

9. Progressing Anti-cancerous Treatment for Lung Cancer

Nihon Naika Gakkai Zasshi, 2022/02/20, Vol.111(Suppl), pp.133b-133b

Maemondo, Makoto

2022

Volltextzugriff (PDF)

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Volltextzugriff (PDF)

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1394-1400

2009

Volltextzugriff (PDF)

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Cancer science, 2018-09, Vol.109 (9), p.2863-2872

2018

Volltextzugriff (PDF)

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3340-3346

2006

Volltextzugriff (PDF)

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1515-1521

2017

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

International journal of clinical oncology, 2022-04, Vol.27 (4), p.695-706

2022

Volltextzugriff (PDF)

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Volltextzugriff (PDF)

Morphological and Molecular Characteristics in Low Grade Fetal Adenocarcinoma of the Lung: Two Case Reports and Literature Review

International journal of surgical pathology, 2022-10, Vol.30 (7), p.797-803

2022

Volltextzugriff (PDF)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Cancer science, 2017-05, Vol.108 (5), p.1000-1006

2017

Volltextzugriff (PDF)

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5401-5406

2008

Volltextzugriff (PDF)

Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor

BMJ case reports, 2019-12, Vol.12 (12), p.e231520

2019

Volltextzugriff (PDF)

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

International journal of clinical oncology, 2022-01, Vol.27 (1), p.112-120

2022

Volltextzugriff (PDF)

Significance of Persistent Systemic Support in the Clinical Course of Delayed Post-hypoxic Leukoencephalopathy Following Severe Coronavirus Disease 2019

Internal Medicine, 2024/04/15, Vol.63(8), pp.1167-1172

2024

Volltextzugriff (PDF)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation

Cancers, 2023-08, Vol.15 (17), p.4231

2023

Volltextzugriff (PDF)

NEJ026 trial: progression-free survival benefit is not enough – Author's reply

The lancet oncology, 2019-07, Vol.20 (7), p.e345-e345

Maemondo, Makoto

2019

Volltextzugriff (PDF)

Association between Family History of Cancer and Lung Cancer Risk among Japanese Men and Women

The Tohoku Journal of Experimental Medicine, 2019, Vol.247(2), pp.99-110

2019

Volltextzugriff (PDF)

The Role of Smoking Status on the Progression‐Free Survival of Non‐Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First‐Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta‐Analysis of Prospective Randomized Trials

The oncologist (Dayton, Ohio), 2015-03, Vol.20 (3), p.307-315

2015

Volltextzugriff (PDF)

The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma

Frontiers in oncology, 2021-10, Vol.11, p.752005-752005

2021

Volltextzugriff (PDF)

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

EBioMedicine, 2020-07, Vol.57, p.102861-102861, Article 102861

2020

Volltextzugriff (PDF)

Cigarette smoking and lung cancer risk according to histologic type in Japanese men and women

Cancer science, 2013-11, Vol.104 (11), p.1515-1522

2013

Volltextzugriff (PDF)

Pleomorphic carcinoma of the trachea after chemoradiotherapy for laryngeal cancer

BMJ case reports, 2020-10, Vol.13 (10), p.e236819

2020

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(205)

Publikationsform

Artikel
(209)
Berichte
(3)

Sprache

Englisch
(185)
Japanisch
(63)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(114)
Science & Technology
(114)
Humans
(90)
Oncology
(86)
Female
(63)
Lung Neoplasms - Drug Therapy
(55)
Male
(55)
Aged
(52)
Middle Aged
(49)
Lung Cancer
(47)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(46)
Chemotherapy
(35)
Mutation
(34)
Lung Neoplasms - Genetics
(33)
Tumors
(33)
Adult
(31)
Carcinoma, Non-Small-Cell Lung - Genetics
(30)
Treatment Outcome
(29)
Respiratory System
(28)
Aged, 80 And Over
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

9. Progressing Anti-cancerous Treatment for Lung Cancer

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Morphological and Molecular Characteristics in Low Grade Fetal Adenocarcinoma of the Lung: Two Case Reports and Literature Review

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

Significance of Persistent Systemic Support in the Clinical Course of Delayed Post-hypoxic Leukoencephalopathy Following Severe Coronavirus Disease 2019

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation

NEJ026 trial: progression-free survival benefit is not enough – Author's reply

Association between Family History of Cancer and Lung Cancer Risk among Japanese Men and Women

The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

Cigarette smoking and lung cancer risk according to histologic type in Japanese men and women

Pleomorphic carcinoma of the trachea after chemoradiotherapy for laryngeal cancer

Suchergebnisse filtern